The protective action of topiramate on dopaminergic neurons

Case Reports and Clinical Practice Review

Volumn 16, Issue 9, 2010, Pages 307-312

  Huang, Shengming ^a   Wang, Haizhen ^a   Xu, Yuming ^a   Zhao, Xinyu ^a   Teng, Junfang ^a   Zhang, Yunhan ^a  

^a THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

6 hydroxydopamine; Dopaminergic neurons; Parkinson disease; Topiramate

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; MICROTUBULE ASSOCIATED PROTEIN 2; OXIDOPAMINE; PROPIDIUM IODIDE; TOPIRAMATE; TYROSINE 3 MONOOXYGENASE; DOPAMINE; DRUG DERIVATIVE; FORMAZAN; FRUCTOSE; MICROTUBULE ASSOCIATED PROTEIN; MTT FORMAZAN; NEUROPROTECTIVE AGENT; PIBENZIMOL; TETRAZOLIUM;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL ADHESION; CELL ASSAY; CELL MEMBRANE PERMEABILITY; CELL METABOLISM; CELL STRUCTURE; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOPAMINERGIC NERVE CELL; DRUG EFFECT; DRUG MECHANISM; EMBRYO; FLUORESCENCE MICROSCOPY; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE TEST; MESENCEPHALON; MOUSE; NERVE CELL DIFFERENTIATION; NERVE CELL GROWTH; NEUROPROTECTION; NONHUMAN; RAT; ANIMAL; CELL COUNT; CELL DEATH; CELL PROLIFERATION; CELL SHAPE; CYTOLOGY; ENZYMOLOGY; FLUORESCENT ANTIBODY TECHNIQUE; METABOLISM; NERVE CELL; SPRAGUE DAWLEY RAT; STAINING; ANIMAL EXPERIMENT; ANIMAL MODEL; DRUG ACTIVITY; IMMUNOFLUORESCENCE; NERVE CELL CULTURE; PARKINSON DISEASE;

ANIMALS; BISBENZIMIDAZOLE; CELL COUNT; CELL DEATH; CELL PROLIFERATION; CELL SHAPE; DOPAMINE; FLUORESCENT ANTIBODY TECHNIQUE; FORMAZANS; FRUCTOSE; MICROTUBULE-ASSOCIATED PROTEINS; NEURONS; NEUROPROTECTIVE AGENTS; PROPIDIUM; RATS; RATS, SPRAGUE-DAWLEY; STAINING AND LABELING; TETRAZOLIUM SALTS; TYROSINE 3-MONOOXYGENASE;

EID: 77956948667     PISSN: 15076164     EISSN: 16433742     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. McDonald WM, Richard IH, DeLong MR: Prevalence, etiology, and treatment of depression in Parkinson's disease. Biol Psychiatry, 2003; 54(3): 363-375
2. Nunes I, Tovmasian LT., Silva RM et al: Pitx3 is required for development of substantia nigra dopaminergic neurons. Proc Natl Acad Sci USA, 2003; 100(7): 4245-4250
3. Adi N, Mash DC, Ali Y et al: Melatonin MT1 and MT2 receptor expression in Parkinson's disease. Med Sci Monit, 2010; 16(2): 61-67
4. Park DH, Eve DJ, Borlongan CV et al: From the basics to application of cell therapy, a steppingstone to the conquest of neurodegeneration: A meeting report. Med Sci Monit, 2009; 15(2): RA23-RA31
5. Olanow CW: Can we achieve neuroprotection with currently available anti-parkinsonian interventions? Neurology, 2009; 72(Suppl.7): S59-S64
6. Valeikiene V, Ceremnych J, Alekna V, Juozulynas A: Differences in WHOQOL-100 domain scores in Parkinson's disease and osteoarthritis. Med Sci Monit, 2008; 14(4): CR221-CR227
7. Liu Y, Barks JD, Xu G, Silverstein FS: Topiramate extends the therapeutic window for hypothermia-mediated neuroprotection after stroke in neonatal rats. Stroke, 2004; 35(6): 1460-1465
8. Edmonds HL Jr, Jiang YD, Zhang PY, Shank R: Topiramate as a neuro-protectant in a rat model of global ischemia-induced neurodegeneration. Life Sci, 2001; 69(19): 2265-2277
9. Lee SR, Kim SP, Kim JE: Protective effect of topiramate against hippo-campal neuronal damage after global ischemia the gerbils. Neurosci Lett, 2000; 281(2): 183-186
10. Sawada H, Kawamura T, Shimohama S et al: Different mechanisms of glutamate-induced neuronal death between dopaminergic and non-dopaminergic neurons in rat mesencephalic culture. J Neurosci Res, 1996; 43(4): 503-510
11. Angehagen M, Ben-Menachem E, Rönnbäck L, Hansson E: Novel mechanisms of action of three antiepileptic drugs, Vigabatrin, Tiagabine, and Topiramate. Neurochem Res, 2003; 28(2): 333-340
12. Niebauer M, Gruenthal M: Topiramate reduces neuronal injury after experimental status epilepticus. Brain Res, 1999; 837(1-2): 263-269
13. Kubera M, Budziszewska B, Jaworska-Feil L et al: Effect of topiramate on the kainate-induced status epilepticus, lipid peroxidation and immunoreactivity of rats. Pol J Pharmacol, 2004; 56(5): 553-561
14. Maragakis NJ, Jackson M, Ganel R, Rothstein JD: Topiramate protects against motor neuron degeneration in organotypic spinal cord cultures but not in G93A SOD1 transgenic mice. Neurosci Lett, 2003; 338(2): 107-110
15. Khan SH, Wright SL, Banigesh A et al: Antiischemic effects of topira-mate in a transient global forebrain ischemia model: Neurochemical, histological, and behavioral evaluation. Neurochem Res, 2003; 28(8): 1235-1239
16. Han SK, Mytilineou C, Cohen G: L-DOPA upregulates glutathione and protects mesencephalic cultures against oxidative stress. Neurochem, 1996; 66(2): 501-510
17. Gille G, Rausch WD, Hung ST et al: Pergolide protects dopaminergic neurons in primary culture under stress conditions. J Neural Transm, 2002; 109(5-6): 633-643
18. Sánchez-Iglesias S, Rey P, Méndez-Alvarez E et al: Time-course of brain oxidative damage caused by intrastriatal administration of 6-hydroxydopamine in a rat model of Parkinson's disease. Neurochem Res, 2007; 32(1): 99-105
19. Zhang X, Velumian AA, Jones OT, Carlen PL: Modulation of high-voltage- activated calcium channels in dentate granule cells by topiramate. Epilepsia, 2000; 41(Suppl.1): S52-S60
20. White HS, Brown SD, Woodhead JH et al: Topiramate modulates GABAevoked currents in murine cortical neurons by a nonbenzodiazepine machanism. Epilepsia, 2000; 41(Suppl.1): S17-S20
21. Poulsen CF, Simeone TA, Maar TE et al: Modulation by TPM of AMPA and kainate mediated calcium influx in cultured cerebral cortical, hippocampal and cerebellar neurons. Neurochem Res, 2004; 29(1): 275-282
22. Shorvon SD: Safety of topiramate: adverse event relationship to dosing. Epilepsia, 1996; 37(Suppl.2): S18-S22
23. Silberstein SD, Ben-Menachem E, Shank RP, Wiegand F: Topiramate monotherapy in epilepsy and migraine prevention. Clin Ther, 2005; 27(2): 154-165
24. Peeters K, Adriaenssen I, Wapenaar R et al: A pooled analysis of adjunctive topiramate in refractory partial epilepsy. Acta Neurol Scand, 2003; 108(1): 9-15